Big Cypress Acquisition Corp.: insider trades · United States · SEC (Form 4)

About Big Cypress Acquisition Corp.

Big Cypress Acquisition Corp. (NYSE/NASDAQ: BCYP) was a U.S.-based special purpose acquisition company, incorporated in Delaware on November 12, 2020, and created to pursue a business combination rather than operate a conventional standalone business. In its IPO materials, the company stated that it had not selected a specific target and intended to focus its search on the life sciences industry. That positioning is important for investors because it explains why BCYP is best understood as a capital-markets vehicle that was designed to bring a future operating business to the public markets. The company’s common stock traded on the Nasdaq under the symbol BCYP during its SPAC phase. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1833214/000149315221000839/form424b4.htm?utm_source=openai)) The key corporate milestone was the closing of BCYP’s business combination with SAB Biotherapeutics on October 22, 2021. Following that transaction, the combined company’s filings show that the legacy operating business continued under a new public-company structure, while the BCYP shell ceased to be the primary operating story. In later SEC documents, the successor company is described as SAB Biotherapeutics, Inc., and current disclosures refer to SAB BIO. For SEO and investor-context purposes, BCYP therefore functions mainly as the historical SPAC ticker linked to the creation of a publicly listed biotechnology company. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1833214/000119312522111227/d322047dposam.htm?utm_source=openai)) The operating company that emerged from BCYP’s transaction is a clinical-stage biopharmaceutical company focused on fully human immunoglobulin programs for autoimmune disease. Recent SEC-filed press releases describe SAB BIO as developing SAB-142, a candidate for type 1 diabetes and other autoimmune diseases, with ongoing Phase 1 data updates in March and April 2026. That makes the story highly development-driven: the investment case depends on clinical readouts, regulatory progress, manufacturing execution, and future financing rather than on established product sales. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1833214/000119312526099376/sabs-20260310.htm?utm_source=openai)) From a competitive standpoint, the company sits in a crowded but potentially high-value autoimmune and biologics landscape. Its differentiation, based on company disclosures, is a platform for generating fully human targeted immunoglobulins intended to address serious unmet medical needs. The public-market narrative has therefore centered on pipeline validation and data generation, including additional phase 1 findings in 2026 and ongoing clinical-trial advancement. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1833214/000119312526114730/sabs-ex99_1.htm?utm_source=openai)) Geographically, Big Cypress’ historical address was in Miami Beach, Florida, and current SAB BIO communications are issued from Miami, confirming a U.S. operating footprint and a U.S. listing context. For French-speaking investors in France, Belgium, and Switzerland, the most useful framing is that BCYP is no longer a conventional operating company to analyze on revenue multiples; rather, it is the former SPAC identity that led to the Nasdaq-listed U.S. biotech now advancing autoimmune-disease programs. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1394645/000149315221025508/xslF345X03/ownership.xml?utm_source=openai))